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were estimated by expert opinion. If two or more studies esti-
mated utility for a similar disease state then a meta-analysis was
carried out to pool the variance weighted mean estimates.
RESULTS: Twenty-eight studies measured utilities of liver dis-
eases or disease states. Only nine of these studies were eligible
for meta-analysis for four health states in chronic liver disease
patients (compensated cirrhosis, decompensated cirrhosis, pre-
liver transplant and post-liver transplant) and three in Hepatitis
C patients (compensated cirrhosis, decompensated cirrhosis and
post-liver transplant). The pooled mean estimates in chronic liver
disease and hepatitis C patients with compensated cirrhosis were
0.87 (95% CI 0.62 to 1.12) and 0.83 (95% CI 0.68 to 0.99)
respectively. For decompensated cirrhosis they were 0.68 (95%
CI 0.40 to 0.95) and 0.73 (95% CI 0.50 to 0.97). For post-liver
transplant, the estimates were 0.70 (95% CI 0.40 to 1.01) and
0.76 (95% CI 0.52 to 1.01) respectively. Pre-liver transplant
patients with chronic liver disease had a utility estimate of 0.57
(95% CI 0.28 to 0.87). CONCLUSIONS: We have estimated
summaries of patient utilities for the major states of chronic liver
disease and hepatitis C, and created a valuable liver disease-
based utility resource for researchers and policy makers.
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ARE ADULTS MORE AVERSE TO TREATMENT RISKS FOR THEIR
CHILDREN THAN THEY ARE FOR THEMSELVES?
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OBJECTIVE: Compare maximum acceptable risk (MAR) of
treatment-related serious adverse events (SAE) between adult
Crohn’s disease (CD) patients and parents of children with CD.
Information on beneﬁt-risk tradeoffs may aid clinicians and reg-
ulatory agencies in their decision-making. METHODS: An on-
line panel of adult CD patients and parents of children with CD
completed a series of choice-format conjoint tradeoff tasks. The
treatment attributes included daily symptom severity and activ-
ity limitations, the potential for serious disease complications,
the time between ﬂare-ups, oral steroid use, and varying levels
of three SAE mortality risks: serious infection, progressive mul-
tifocal leukoencephalopathy (PML) and lymphoma. The annual
MAR was calculated for 15 SAE-clinical beneﬁt combinations (3
SAEs X 5 levels of clinical improvement from a severe or mod-
erate CD state). RESULTS: A total of 357 adult patients and 105
parents completed the survey. Improvements in daily symptom
severity were the most important factor in treatment preferences.
Higher MAR (greater risk acceptance) was observed for trade-
off tasks involving higher levels of clinical beneﬁt. Compared to
adult patients, parents were willing to accept a greater SAE risk
for alleviation of severe CD symptoms (for 7 of 9 SAE vs. clin-
ical beneﬁt combinations), but were less willing to accept SAE
risk for improvement of moderate CD symptoms (for 6 of 6 com-
binations). CONCLUSIONS: Medical interventions carry risks
of adverse outcomes that must be evaluated against their clini-
cal beneﬁts. Adult patients and parents of children with CD indi-
cated they are willing to accept deﬁned mortality risks in
exchange for clinical efﬁcacy. While parents were more willing
to accept higher SAE risks for improvement of severe CD symp-
toms, patients were willing to accept higher risks for improve-
ment of moderate CD symptoms.
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DEPICTION OF GASTROESOPHAGEAL REFLUX DISEASE
(GERD) PREVALENCE IN PRIMARY CARE IN GREECE
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OBJECTIVES: GERD is a frequent condition among the general
population, which is not often properly diagnosed or treated.
The study aimed to depict the prevalence of GERD within a
primary care setting, assess symptoms severity and frequency in
GERD patients, and to examine the association between GERD
and aspirin/NSAIDs use. METHODS: A total of 2878 individu-
als (M/F: 1411/1467, mean age 55, 19 ± 14,5 years, BMI 26, 7
± 3, 9 Kg/m2) visiting 300 Primary Care Practitioners (PCP)
between November-December 2005 were included. Demo-
graphic and medical history data including aspirin/NSAID use,
the presence and severity-frequency of GERD and dyspepsia
symptoms were recorded, using a structured questionnaire.
GERD (heartburn, regurgitation) and dyspepsia (epigastric pain,
early satiety, postprandial fullness) diagnoses were based on
widely accepted epidemiological criteria. RESULTS: The main
reasons for patients visiting PCPs were prescription renewal
(32.9%) and consultation for upper GI symptoms (28.6%).
GERD symptoms were reported by 57.4% and dyspepsia by
67.6% of the 2878 patients during the last week before visiting
their PCP. Among patients with upper GI symptoms, GERD or
dyspepsia was reported almost equally as predominant symptom
by 34.2% and 35.6% of patients respectively, while another
4.9% reported symptoms of both diagnoses as predominant.
GERD symptoms were mild in 33%, moderate in 40% and
severe in 12% of the patients, while present for 2 days/week in
29%, 3–5 days/week in 39% and 6–7 days/week in 17% of
cases. GERD and/or dyspepsia symptoms were reported by
81.7% of users and as opposed to 62.5% of non-aspirin/NSAID
users during the last two weeks before visiting their PCP (P =
0.043). CONCLUSIONS: In patients who use primary care
health resources, GERD symptoms are highly prevalent (57%),
being present for at least 2 days/week in 85% and of moder-
ate/severe intensity in more than 50% of symptomatic patients.
Aspirin/NSAID use substantially increases prevalence of GERD
and dyspepsia symptoms.
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The validity of the work productivity and activity impairment
(WPAI) questionnaire in the measurement of health-related pro-
ductivity was demonstrated in gastroesophageal reﬂux disease
and irritable bowel syndrome. The Crohn’s disease (CD) speciﬁc
WPAI (WPAI:CD) was administered in two large clinical trials
PRECiSE 1 and PRECiSE 2 that demonstrated the efﬁcacy and
tolerability of Certolizumab Pegol subcutaneous once monthly,
vs. placebo, in patients with moderate to severe CD. OBJEC-
TIVES: The objective was to compare the WPAI : CD scores of
patients categorized by baseline disease severity and health-
related quality of life (HRQoL) level, with the a priori assump-
tion that more severe health conditions are associated with
higher impairments in work productivity and daily activities.
METHODS: The 1330 randomized patients were divided into
“best” and “worst” subgroups determined by the CD Activity
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Index (CDAI), SF-36, and EQ-5D. “Best” health was identiﬁed
by CDAI scores < median, SF-36 Physical and Mental Compo-
nent Scores (PCS and MCS) ≥ median, and modality “1”
responses to the EQ-5D dimensions. The non-parametric
Wilcoxon test was used to compare the WPAI : CD scores
between the subgroups. RESULTS: CD patients with the “worst”
disease severity (CDAI > 288.1) showed higher impairment in
work (+8.9%) and activities (+10.0%) vs. patients with “best”
health. Similarly patients with “worst” HRQoL, as demon-
strated by SF-36 PCS < 37.5 and MCS < 37.4, showed higher
impairments in work (+20.0% by PCS, +18.5% by MCS) and
activities (+22.2% by PCS, +15.5% by MCS) vs. “best” HRQoL.
Patients with the “worst” EQ-5D states reported more impair-
ment in work (+15.2% averaged over the 5 dimensions) and
activities (+17.3%) vs. patients with the “best” states. All 
p-values were <0.001. CONCLUSION: The measurement of
expected differences in work and activity impairment by disease
severity and HRQoL levels supports the discriminant validity of
the WPAI : CD.
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OBJECTIVES: Gastroesophageal reﬂux disease (GERD) inter-
feres with work productivity through two main mechanisms.
Nighttime symptoms disturb sleep and cause daytime tiredness,
while daytime symptoms affect work productivity by interrupt-
ing physical and social activities. A recent systematic review
using data in general working populations from three separate
studies indicated that GERD causes a reduction in productivity
while at work of around 10%. The level of work productivity is
strongly associated with symptom severity, symptom frequency,
and the occurrence of nighttime symptoms. Hence, levels con-
siderably higher than 10% have been observed in untreated
patients with troublesome symptoms, e.g. up to 40% in patients
with GERD-related sleep disturbances. The objective of this
study was to estimate the effects of GERD on productivity while
at work in France. METHODS: Work productivity data from
two international studies in general working populations (n =
1111 and 1516, respectively) were used to compare results from
the French sub-populations with overall results. Based on the
results of these French sub-populations, estimation was made 
of the total work time lost because of GERD-related reduced
work productivity. RESULTS: Findings from the French sub-
populations were consistent with overall ﬁndings from the total
samples, which indicated that GERD causes an average reduc-
tion in at-work productivity of around 10%. Assuming a French
population of 36 million in working age, a prevalence of diag-
nosed GERD of approximately 10% and that 63% of GERD
patients are employed and work around 36 hours per week, then
it can be estimated that GERD causes an at-work productivity
loss corresponding to around 380 million work hours per year
in France. CONCLUSIONS: Intermediated through reduced
productivity while at work, GERD symptoms have implications
well beyond the individual patient perspective in terms of
number of work hours lost for the French community.
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OBJECTIVES: To explore the association between work pro-
ductivity and response to treatment with proton pump inhibitors
(PPIs) in patients with gastroesophageal reﬂux disease (GERD).
METHODS: Interviews were conducted with 1908 patients with
symptoms of GERD in the USA, UK, Germany and France.
Patients diagnosed with GERD who were receiving PPIs were
classiﬁed as complete responders (no symptoms), well-controlled
(used a PPI compliantly, experienced an improvement in or
decrease in frequency of symptoms, and suffered key GERD
symptoms on ≤1 of the past seven days), incomplete responders
(the same deﬁnition as well-controlled but with symptoms on ≥2
of the past seven days), or non-responders (no improvement or
symptoms worsened). Information obtained included GERD-
related absence from work and reduced productivity while at
work because of GERD during the past seven days. RESULTS:
The analysis included 237 employed patients on PPI treatment.
The mean number of hours absent from work because of GERD
was 0.1 for complete responders (n = 57), 0.1 for well-controlled
(n = 32), 0.5 for incomplete responders (n = 128), and 1.3 for
non-responders (n = 20). The mean percentage reduced produc-
tivity while at work was 4.3% for complete responders, 7.8%
for well-controlled, 14.9% for incomplete responders, and
17.6% for non-responders. When pooling results for complete
responders and well-controlled vs. incomplete responders and
non-responders, mean differences between these two groups
were 0.5 hours absence (0.1 vs. 0.6, p < 0.05) and a 9.7% reduc-
tion in work productivity (5.6% vs. 15.3%, p < 0.0001). The
9.7% difference in reduced productivity while at work corre-
sponds to an equivalent of 3.9 work hours lost (% reduced pro-
ductivity x hours worked) per patient, based on a 40-hour
working week. CONCLUSIONS: There are signiﬁcant differ-
ences in GERD-related work productivity depending on response
to medical treatment, which suggests that strategies for improv-
ing management of GERD may be warranted.
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OBJECTIVES: To explore cost-effectiveness of prophylaxis with
Refacto® (B-domain-deleted recombinant FVIII) in adults with
hemophilia A. METHODS: A prospective, open, uncontrolled
study was designed. Patients with hemophilia A aged 18 years
or more, with frequent bleeding episodes, switching from on-
demand treatment (ODT) to prophylaxis (PT), have been
enrolled. All patients were treated with 25 IU/Kg of Refacto® 3
times-a-week for all the 6-month study period. Bleeding event
rate and FVIII concentrate consumption have been evaluated
over on-demand treatment time period (ODP), 6 months before
enrolment, and the prophylaxis time period (PP), 6 months after
enrolment. Medical costs (that represent 99% of total costs) have
